ID   ALDOA_HUMAN             Reviewed;         364 AA.
AC   P04075; B4DXI7; Q6FH76; Q6FI10; Q96B15; Q9BWD9; Q9UCN2;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   26-FEB-2020, entry version 236.
DE   RecName: Full=Fructose-bisphosphate aldolase A;
DE            EC=4.1.2.13;
DE   AltName: Full=Lung cancer antigen NY-LU-1;
DE   AltName: Full=Muscle-type aldolase;
GN   Name=ALDOA; Synonyms=ALDA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=3840020; DOI=10.1016/0006-291x(85)91818-2;
RA   Sakakibara M., Mukai T., Hori K.;
RT   "Nucleotide sequence of a cDNA clone for human aldolase: a messenger RNA in
RT   the liver.";
RL   Biochem. Biophys. Res. Commun. 131:413-420(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fibroblast;
RX   PubMed=3030757; DOI=10.1111/j.1432-1033.1987.tb10984.x;
RA   Izzo P., Costanzo P., Lupo A., Rippa E., Borghese A.M., Paolella G.,
RA   Salvatore F.;
RT   "A new human species of aldolase A mRNA from fibroblasts.";
RL   Eur. J. Biochem. 164:9-13(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3391172; DOI=10.1111/j.1432-1033.1988.tb14136.x;
RA   Izzo P., Costanzo P., Lupo A., Rippa E., Paolella G., Salvatore F.;
RT   "Human aldolase A gene. Structural organization and tissue-specific
RT   expression by multiple promoters and alternate mRNA processing.";
RL   Eur. J. Biochem. 174:569-578(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1999195; DOI=10.1111/j.1432-1033.1991.tb15766.x;
RA   Mukai T., Arai Y., Yatsuki H., Joh K., Hori K.;
RT   "An additional promoter functions in the human aldolase A gene, but not in
RT   rat.";
RL   Eur. J. Biochem. 195:781-787(1991).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix, Eye, Lung, Testis, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-108 (ISOFORM 1).
RX   PubMed=3441006; DOI=10.1016/0022-2836(87)90556-0;
RA   Maire P., Gautron S., Hakim V., Gregori C., Mennecier F., Kahn A.;
RT   "Characterization of three optional promoters in the 5' region of the human
RT   aldolase A gene.";
RL   J. Mol. Biol. 197:425-438(1987).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-364.
RX   PubMed=3355497; DOI=10.1042/bj2490779;
RA   Freemont P.S., Dunbar B., Fothergill-Gilmore L.A.;
RT   "The complete amino acid sequence of human skeletal-muscle fructose-
RT   bisphosphate aldolase.";
RL   Biochem. J. 249:779-788(1988).
RN   [12]
RP   PROTEIN SEQUENCE OF 2-63 AND 148-358.
RX   PubMed=6696436; DOI=10.1016/0003-9861(84)90075-4;
RA   Freemont P.S., Dunbar B., Fothergill L.A.;
RT   "Human skeletal-muscle aldolase: N-terminal sequence analysis of CNBr- and
RT   o-iodosobenzoic acid-cleavage fragments.";
RL   Arch. Biochem. Biophys. 228:342-352(1984).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-22.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [14]
RP   PROTEIN SEQUENCE OF 2-16.
RC   TISSUE=Colon carcinoma;
RX   PubMed=1353685; DOI=10.1016/0167-4889(92)90078-p;
RA   Lee K.N., Maxwell M.D., Patterson M.K. Jr., Birckbichler P.J., Conway E.;
RT   "Identification of transglutaminase substrates in HT29 colon cancer cells:
RT   use of 5-(biotinamido)pentylamine as a transglutaminase-specific probe.";
RL   Biochim. Biophys. Acta 1136:12-16(1992).
RN   [15]
RP   PROTEIN SEQUENCE OF 2-13; 29-42; 44-56; 61-69; 88-99; 154-173; 244-258 AND
RP   332-342, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 139-364 (ISOFORM 1/2).
RX   PubMed=3674018;
RA   Tolan D.R., Niclas J., Bruce B.D., Lebo R.V.;
RT   "Evolutionary implications of the human aldolase-A, -B, -C, and
RT   - pseudogene chromosome locations.";
RL   Am. J. Hum. Genet. 41:907-924(1987).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Lymphoblast;
RX   PubMed=14654843; DOI=10.1038/nature02166;
RA   Andersen J.S., Wilkinson C.J., Mayor T., Mortensen P., Nigg E.A., Mann M.;
RT   "Proteomic characterization of the human centrosome by protein correlation
RT   profiling.";
RL   Nature 426:570-574(2003).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   INTERACTION WITH FBP2.
RX   PubMed=18214967; DOI=10.1002/prot.21909;
RA   Gizak A., Maciaszczyk E., Dzugaj A., Eschrich K., Rakus D.;
RT   "Evolutionary conserved N-terminal region of human muscle fructose 1,6-
RT   bisphosphatase regulates its activity and the interaction with aldolase.";
RL   Proteins 72:209-216(2008).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36 AND SER-39, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [23]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-42; LYS-108 AND LYS-330, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-36 AND SER-39, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   MALONYLATION AT LYS-111 AND LYS-312.
RX   PubMed=21908771; DOI=10.1074/mcp.m111.012658;
RA   Peng C., Lu Z., Xie Z., Cheng Z., Chen Y., Tan M., Luo H., Zhang Y., He W.,
RA   Yang K., Zwaans B.M., Tishkoff D., Ho L., Lombard D., He T.C., Dai J.,
RA   Verdin E., Ye Y., Zhao Y.;
RT   "The first identification of lysine malonylation substrates and its
RT   regulatory enzyme.";
RL   Mol. Cell. Proteomics 10:M111.012658.01-M111.012658.12(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39 AND SER-46, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [29]
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-9; SER-36; SER-39 AND SER-46,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-39; SER-46 AND SER-272, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.o113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V., Aguiar M.,
RA   Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C., Vemulapalli V.,
RA   Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [34]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-42, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [36]
RP   HYDROXYBUTYRYLATION AT LYS-99.
RX   PubMed=29775581; DOI=10.1016/j.molcel.2018.04.011;
RA   Huang H., Tang S., Ji M., Tang Z., Shimada M., Liu X., Qi S.,
RA   Locasale J.W., Roeder R.G., Zhao Y., Li X.;
RT   "p300-mediated lysine 2-hydroxyisobutyrylation regulates glycolysis.";
RL   Mol. Cell 70:663-678(2018).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS).
RX   PubMed=2335208; DOI=10.1016/0014-5793(90)80211-z;
RA   Gamblin S.J., Cooper B., Millar J.R., Davies G.J., Littlechild J.A.,
RA   Watson H.C.;
RT   "The crystal structure of human muscle aldolase at 3.0-A resolution.";
RL   FEBS Lett. 262:282-286(1990).
RN   [38]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS).
RX   PubMed=2056525; DOI=10.1016/0022-2836(91)90650-u;
RA   Gamblin S.J., Davies G.J., Grimes J.M., Jackson R.M., Littlechild J.A.,
RA   Watson H.C.;
RT   "Activity and specificity of human aldolases.";
RL   J. Mol. Biol. 219:573-576(1991).
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS).
RX   PubMed=10048322; DOI=10.1110/ps.8.2.291;
RA   Dalby A., Dauter Z., Littlechild J.A.;
RT   "Crystal structure of human muscle aldolase complexed with fructose 1,6-
RT   bisphosphate: mechanistic implications.";
RL   Protein Sci. 8:291-297(1999).
RN   [40]
RP   VARIANT GSD12 GLY-129, AND CHARACTERIZATION OF VARIANT GSD12 GLY-129.
RX   PubMed=2825199; DOI=10.1073/pnas.84.23.8623;
RA   Kishi H., Mukai T., Hirono A., Fujii H., Miwa S., Hori K.;
RT   "Human aldolase A deficiency associated with a hemolytic anemia:
RT   thermolabile aldolase due to a single base mutation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8623-8627(1987).
RN   [41]
RP   CHARACTERIZATION OF VARIANT GSD12 GLY-129.
RX   PubMed=2229018; DOI=10.1093/oxfordjournals.jbchem.a123174;
RA   Takasaki Y., Takahashi I., Mukai T., Hori K.;
RT   "Human aldolase A of a hemolytic anemia patient with Asp-128-->Gly
RT   substitution: characteristics of an enzyme generated in E. coli transfected
RT   with the expression plasmid pHAAD128G.";
RL   J. Biochem. 108:153-157(1990).
RN   [42]
RP   VARIANT GSD12 LYS-207.
RX   PubMed=8598869; DOI=10.1056/nejm199604253341705;
RA   Kreuder J., Borkhardt A., Repp R., Pekrun A., Goettsche B., Gottschalk U.,
RA   Reichmann H., Schachenmayr W., Schlegel K., Lampert F.;
RT   "Brief report: inherited metabolic myopathy and hemolysis due to a mutation
RT   in aldolase A.";
RL   N. Engl. J. Med. 334:1100-1104(1996).
RN   [43]
RP   VARIANT GSD12 TYR-339.
RX   PubMed=14615364; DOI=10.1182/blood-2003-09-3160;
RA   Yao D.C., Tolan D.R., Murray M.F., Harris D.J., Darras B.T., Geva A.,
RA   Neufeld E.J.;
RT   "Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous
RT   mutations of the gene for erythrocyte/muscle isozyme of aldolase,
RT   ALDOA(Arg303X/Cys338Tyr).";
RL   Blood 103:2401-2403(2004).
RN   [44]
RP   VARIANT GSD12 SER-347, BIOPHYSICOCHEMICAL PROPERTIES, AND CHARACTERIZATION
RP   OF VARIANTS GSD12 LYS-207 AND SER-347.
RX   PubMed=14766013; DOI=10.1042/bj20031941;
RA   Esposito G., Vitagliano L., Costanzo P., Borrelli L., Barone R., Pavone L.,
RA   Izzo P., Zagari A., Salvatore F.;
RT   "Human aldolase A natural mutants: relationship between flexibility of the
RT   C-terminal region and enzyme function.";
RL   Biochem. J. 380:51-56(2004).
CC   -!- FUNCTION: Plays a key role in glycolysis and gluconeogenesis. In
CC       addition, may also function as scaffolding protein (By similarity).
CC       {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=beta-D-fructose 1,6-bisphosphate = D-glyceraldehyde 3-
CC         phosphate + dihydroxyacetone phosphate; Xref=Rhea:RHEA:14729,
CC         ChEBI:CHEBI:32966, ChEBI:CHEBI:57642, ChEBI:CHEBI:59776; EC=4.1.2.13;
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=52 uM for fructose 1,6-bisphosphate (at 30 degrees Celsius)
CC         {ECO:0000269|PubMed:14766013};
CC       Temperature dependence:
CC         Thermal denaturation midpoint (Tm) is 54.4 degrees Celsius.
CC         {ECO:0000269|PubMed:14766013};
CC   -!- PATHWAY: Carbohydrate degradation; glycolysis; D-glyceraldehyde 3-
CC       phosphate and glycerone phosphate from D-glucose: step 4/4.
CC   -!- SUBUNIT: Homotetramer. Interacts with SNX9 and WAS (By similarity).
CC       Interacts with FBP2; the interaction blocks FBP2 inhibition by
CC       physiological concentrations of AMP and reduces inhibition by Ca(2+).
CC       {ECO:0000250, ECO:0000269|PubMed:18214967}.
CC   -!- INTERACTION:
CC       P09972:ALDOC; NbExp=6; IntAct=EBI-10194102, EBI-2952751;
CC       P05014:IFNA4; NbExp=3; IntAct=EBI-10194102, EBI-10194381;
CC       P12004:PCNA; NbExp=3; IntAct=EBI-709613, EBI-358311;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, myofibril, sarcomere, I band.
CC       Cytoplasm, myofibril, sarcomere, M line. Note=In skeletal muscle,
CC       accumulates around the M line and within the I band, colocalizing with
CC       FBP2 on both sides of the Z line in the absence of Ca(2+).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P04075-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P04075-2; Sequence=VSP_047261;
CC   -!- DISEASE: Glycogen storage disease 12 (GSD12) [MIM:611881]: A metabolic
CC       disorder associated with increased hepatic glycogen and hemolytic
CC       anemia. It may lead to myopathy with exercise intolerance and
CC       rhabdomyolysis. {ECO:0000269|PubMed:14615364,
CC       ECO:0000269|PubMed:14766013, ECO:0000269|PubMed:2229018,
CC       ECO:0000269|PubMed:2825199, ECO:0000269|PubMed:8598869}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: In vertebrates, three forms of this ubiquitous
CC       glycolytic enzyme are found, aldolase A in muscle, aldolase B in liver
CC       and aldolase C in brain.
CC   -!- SIMILARITY: Belongs to the class I fructose-bisphosphate aldolase
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M11560; AAA51690.1; -; mRNA.
DR   EMBL; X05236; CAA28861.1; -; mRNA.
DR   EMBL; X12447; CAA30979.1; -; Genomic_DNA.
DR   EMBL; AK301993; BAG63399.1; -; mRNA.
DR   EMBL; CR536528; CAG38765.1; -; mRNA.
DR   EMBL; CR541880; CAG46678.1; -; mRNA.
DR   EMBL; AC093512; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471238; EAW79933.1; -; Genomic_DNA.
DR   EMBL; BC000367; AAH00367.2; -; mRNA.
DR   EMBL; BC004333; AAH04333.1; -; mRNA.
DR   EMBL; BC010660; AAH10660.1; -; mRNA.
DR   EMBL; BC012880; AAH12880.1; -; mRNA.
DR   EMBL; BC013614; AAH13614.1; -; mRNA.
DR   EMBL; BC015888; AAH15888.1; -; mRNA.
DR   EMBL; BC016170; AAH16170.1; -; mRNA.
DR   EMBL; BC016800; AAH16800.1; -; mRNA.
DR   EMBL; M21190; AAA51697.1; -; mRNA.
DR   CCDS; CCDS10668.1; -. [P04075-1]
DR   CCDS; CCDS58450.1; -. [P04075-2]
DR   PIR; S14084; ADHUA.
DR   RefSeq; NP_000025.1; NM_000034.3.
DR   RefSeq; NP_001121089.1; NM_001127617.2. [P04075-1]
DR   RefSeq; NP_001230106.1; NM_001243177.1. [P04075-2]
DR   RefSeq; NP_908930.1; NM_184041.2. [P04075-1]
DR   RefSeq; NP_908932.1; NM_184043.2. [P04075-1]
DR   RefSeq; XP_011544070.1; XM_011545768.2.
DR   PDB; 1ALD; X-ray; 2.00 A; A=2-364.
DR   PDB; 2ALD; X-ray; 2.10 A; A=2-364.
DR   PDB; 4ALD; X-ray; 2.80 A; A=2-364.
DR   PDB; 5KY6; X-ray; 1.94 A; A/B/C/D=2-364.
DR   PDBsum; 1ALD; -.
DR   PDBsum; 2ALD; -.
DR   PDBsum; 4ALD; -.
DR   PDBsum; 5KY6; -.
DR   SMR; P04075; -.
DR   BioGrid; 106728; 141.
DR   IntAct; P04075; 66.
DR   MINT; P04075; -.
DR   STRING; 9606.ENSP00000378669; -.
DR   ChEMBL; CHEMBL2106; -.
DR   DrugBank; DB04733; 1,6-DI-O-PHOSPHONO-D-MANNITOL.
DR   DrugBank; DB02512; 1,6-Fructose Diphosphate (Linear Form).
DR   DrugBank; DB11638; Artenimol.
DR   DrugBank; DB04326; Dihydroxyacetone phosphate.
DR   DrugBank; DB08240; N-(4-CHLOROPHENYL)-3-(PHOSPHONOOXY)NAPHTHALENE-2-CARBOXAMIDE.
DR   DrugBank; DB01593; Zinc.
DR   DrugBank; DB14487; Zinc acetate.
DR   DrugBank; DB14533; Zinc chloride.
DR   MoonProt; P04075; -.
DR   CarbonylDB; P04075; -.
DR   iPTMnet; P04075; -.
DR   PhosphoSitePlus; P04075; -.
DR   SwissPalm; P04075; -.
DR   BioMuta; ALDOA; -.
DR   DMDM; 113606; -.
DR   DOSAC-COBS-2DPAGE; P04075; -.
DR   OGP; P04075; -.
DR   REPRODUCTION-2DPAGE; IPI00465439; -.
DR   REPRODUCTION-2DPAGE; P04075; -.
DR   SWISS-2DPAGE; P04075; -.
DR   UCD-2DPAGE; P04075; -.
DR   CPTAC; CPTAC-459; -.
DR   EPD; P04075; -.
DR   jPOST; P04075; -.
DR   MassIVE; P04075; -.
DR   PaxDb; P04075; -.
DR   PeptideAtlas; P04075; -.
DR   PRIDE; P04075; -.
DR   ProteomicsDB; 51647; -. [P04075-1]
DR   TopDownProteomics; P04075-1; -. [P04075-1]
DR   DNASU; 226; -.
DR   Ensembl; ENST00000412304; ENSP00000400452; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000563060; ENSP00000455800; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000569545; ENSP00000455700; ENSG00000149925. [P04075-1]
DR   Ensembl; ENST00000642816; ENSP00000496166; ENSG00000149925. [P04075-2]
DR   Ensembl; ENST00000643777; ENSP00000494188; ENSG00000149925. [P04075-1]
DR   GeneID; 226; -.
DR   KEGG; hsa:226; -.
DR   UCSC; uc010veg.3; human. [P04075-1]
DR   CTD; 226; -.
DR   DisGeNET; 226; -.
DR   GeneCards; ALDOA; -.
DR   HGNC; HGNC:414; ALDOA.
DR   HPA; CAB006252; -.
DR   HPA; HPA004177; -.
DR   MalaCards; ALDOA; -.
DR   MIM; 103850; gene.
DR   MIM; 611881; phenotype.
DR   neXtProt; NX_P04075; -.
DR   OpenTargets; ENSG00000149925; -.
DR   Orphanet; 57; Glycogen storage disease due to aldolase A deficiency.
DR   PharmGKB; PA24707; -.
DR   eggNOG; KOG1557; Eukaryota.
DR   eggNOG; COG3588; LUCA.
DR   GeneTree; ENSGT00950000182987; -.
DR   HOGENOM; CLU_031243_0_0_1; -.
DR   InParanoid; P04075; -.
DR   KO; K01623; -.
DR   OMA; DYREMLF; -.
DR   OrthoDB; 799973at2759; -.
DR   PhylomeDB; P04075; -.
DR   TreeFam; TF314203; -.
DR   BioCyc; MetaCyc:HS07647-MONOMER; -.
DR   BRENDA; 4.1.2.13; 2681.
DR   Reactome; R-HSA-114608; Platelet degranulation.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-70171; Glycolysis.
DR   Reactome; R-HSA-70263; Gluconeogenesis.
DR   SABIO-RK; P04075; -.
DR   SIGNOR; P04075; -.
DR   UniPathway; UPA00109; UER00183.
DR   ChiTaRS; ALDOA; human.
DR   EvolutionaryTrace; P04075; -.
DR   GeneWiki; Aldolase_A; -.
DR   GenomeRNAi; 226; -.
DR   Pharos; P04075; Tbio.
DR   PRO; PR:P04075; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; P04075; protein.
DR   Bgee; ENSG00000149925; Expressed in vastus lateralis and 237 other tissues.
DR   ExpressionAtlas; P04075; baseline and differential.
DR   Genevisible; P04075; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:BHF-UCL.
DR   GO; GO:0005623; C:cell; IEA:GOC.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:BHF-UCL.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0031674; C:I band; TAS:BHF-UCL.
DR   GO; GO:0031430; C:M band; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0031093; C:platelet alpha granule lumen; TAS:Reactome.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0061827; C:sperm head; IDA:CAFA.
DR   GO; GO:1904724; C:tertiary granule lumen; TAS:Reactome.
DR   GO; GO:0003779; F:actin binding; TAS:BHF-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0008092; F:cytoskeletal protein binding; IDA:BHF-UCL.
DR   GO; GO:0070061; F:fructose binding; IDA:BHF-UCL.
DR   GO; GO:0004332; F:fructose-bisphosphate aldolase activity; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0015631; F:tubulin binding; TAS:BHF-UCL.
DR   GO; GO:0007015; P:actin filament organization; TAS:BHF-UCL.
DR   GO; GO:0006754; P:ATP biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0007339; P:binding of sperm to zona pellucida; IMP:CAFA.
DR   GO; GO:0061621; P:canonical glycolysis; TAS:Reactome.
DR   GO; GO:0030388; P:fructose 1,6-bisphosphate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006000; P:fructose metabolic process; IMP:BHF-UCL.
DR   GO; GO:0006094; P:gluconeogenesis; TAS:Reactome.
DR   GO; GO:0006096; P:glycolytic process; IMP:BHF-UCL.
DR   GO; GO:0046716; P:muscle cell cellular homeostasis; IMP:BHF-UCL.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0002576; P:platelet degranulation; TAS:Reactome.
DR   GO; GO:0051289; P:protein homotetramerization; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IDA:BHF-UCL.
DR   GO; GO:0006941; P:striated muscle contraction; IMP:BHF-UCL.
DR   Gene3D; 3.20.20.70; -; 1.
DR   InterPro; IPR029768; Aldolase_I_AS.
DR   InterPro; IPR013785; Aldolase_TIM.
DR   InterPro; IPR000741; FBA_I.
DR   Pfam; PF00274; Glycolytic; 1.
DR   PROSITE; PS00158; ALDOLASE_CLASS_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cytoplasm;
KW   Direct protein sequencing; Disease mutation; Glycogen storage disease;
KW   Glycolysis; Hereditary hemolytic anemia; Hydroxylation; Isopeptide bond;
KW   Lyase; Phosphoprotein; Polymorphism; Reference proteome; Schiff base;
KW   Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000244|PubMed:22223895,
FT                   ECO:0000269|PubMed:12665801, ECO:0000269|PubMed:1353685,
FT                   ECO:0000269|PubMed:3355497, ECO:0000269|PubMed:6696436,
FT                   ECO:0000269|Ref.15"
FT   CHAIN           2..364
FT                   /note="Fructose-bisphosphate aldolase A"
FT                   /id="PRO_0000216936"
FT   ACT_SITE        188
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        230
FT                   /note="Schiff-base intermediate with dihydroxyacetone-P"
FT   BINDING         56
FT                   /note="Substrate"
FT   BINDING         147
FT                   /note="Substrate"
FT   SITE            364
FT                   /note="Necessary for preference for fructose 1,6-
FT                   bisphosphate over fructose 1-phosphate"
FT   MOD_RES         5
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P05065"
FT   MOD_RES         9
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         36
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:23186163"
FT   MOD_RES         39
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:19690332,
FT                   ECO:0000244|PubMed:20068231, ECO:0000244|PubMed:21406692,
FT                   ECO:0000244|PubMed:23186163, ECO:0000244|PubMed:24275569"
FT   MOD_RES         42
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         46
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17081983,
FT                   ECO:0000244|PubMed:21406692, ECO:0000244|PubMed:23186163,
FT                   ECO:0000244|PubMed:24275569"
FT   MOD_RES         99
FT                   /note="N6-(2-hydroxyisobutyryl)lysine"
FT                   /evidence="ECO:0000269|PubMed:29775581"
FT   MOD_RES         108
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   MOD_RES         111
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:P09972"
FT   MOD_RES         111
FT                   /note="N6-malonyllysine; alternate"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         132
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05065"
FT   MOD_RES         272
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         312
FT                   /note="N6-malonyllysine"
FT                   /evidence="ECO:0000269|PubMed:21908771"
FT   MOD_RES         330
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000244|PubMed:19608861"
FT   CROSSLNK        42
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0000244|PubMed:25114211"
FT   CROSSLNK        42
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0000244|PubMed:25114211"
FT   VAR_SEQ         1
FT                   /note="M -> MARRKPEGSSFNMTHLSMAMAFSFPPVASGQLHPQLGNTQHQTELGK
FT                   ELATTSTM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047261"
FT   VARIANT         82
FT                   /note="E -> Q (in dbSNP:rs11553107)"
FT                   /id="VAR_048219"
FT   VARIANT         129
FT                   /note="D -> G (in GSD12; thermolabile; dbSNP:rs121909533)"
FT                   /evidence="ECO:0000269|PubMed:2229018,
FT                   ECO:0000269|PubMed:2825199"
FT                   /id="VAR_000550"
FT   VARIANT         142
FT                   /note="G -> V (in dbSNP:rs11553108)"
FT                   /id="VAR_048220"
FT   VARIANT         207
FT                   /note="E -> K (in GSD12; reduces thermal stability; 3-fold
FT                   decrease in catalytic efficiency mostly due to reduced
FT                   substrate affinity; dbSNP:rs121909534)"
FT                   /evidence="ECO:0000269|PubMed:14766013,
FT                   ECO:0000269|PubMed:8598869"
FT                   /id="VAR_044142"
FT   VARIANT         339
FT                   /note="C -> Y (in GSD12)"
FT                   /evidence="ECO:0000269|PubMed:14615364"
FT                   /id="VAR_044143"
FT   VARIANT         347
FT                   /note="G -> S (in GSD12; does not affect thermal stability;
FT                   4-fold decrease in catalytic efficiency due to reduced
FT                   enzyme activity; dbSNP:rs138824667)"
FT                   /evidence="ECO:0000269|PubMed:14766013"
FT                   /id="VAR_044144"
FT   CONFLICT        73
FT                   /note="C -> G (in Ref. 3; CAA30979)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        180
FT                   /note="Q -> R (in Ref. 6; CAG46678)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196
FT                   /note="D -> A (in Ref. 3; CAA30979)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        230
FT                   /note="K -> N (in Ref. 3; CAA30979)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        280
FT                   /note="A -> S (in Ref. 3; CAA30979)"
FT                   /evidence="ECO:0000305"
FT   HELIX           10..23
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          29..33
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           37..40
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           53..64
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           68..70
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   TURN            71..73
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          74..79
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           81..84
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           94..100
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          104..108
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          113..115
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          119..121
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          123..125
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           131..140
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          145..152
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          155..157
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           161..180
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          184..191
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           199..219
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           224..226
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           246..258
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          267..271
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           277..289
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          296..303
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           304..307
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           318..320
FT                   /evidence="ECO:0000244|PDB:1ALD"
FT   HELIX           322..338
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   TURN            339..341
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   STRAND          348..350
FT                   /evidence="ECO:0000244|PDB:1ALD"
FT   HELIX           357..359
FT                   /evidence="ECO:0000244|PDB:5KY6"
FT   HELIX           361..363
FT                   /evidence="ECO:0000244|PDB:5KY6"
SQ   SEQUENCE   364 AA;  39420 MW;  0AAED80F755A7BE8 CRC64;
     MPYQYPALTP EQKKELSDIA HRIVAPGKGI LAADESTGSI AKRLQSIGTE NTEENRRFYR
     QLLLTADDRV NPCIGGVILF HETLYQKADD GRPFPQVIKS KGGVVGIKVD KGVVPLAGTN
     GETTTQGLDG LSERCAQYKK DGADFAKWRC VLKIGEHTPS ALAIMENANV LARYASICQQ
     NGIVPIVEPE ILPDGDHDLK RCQYVTEKVL AAVYKALSDH HIYLEGTLLK PNMVTPGHAC
     TQKFSHEEIA MATVTALRRT VPPAVTGITF LSGGQSEEEA SINLNAINKC PLLKPWALTF
     SYGRALQASA LKAWGGKKEN LKAAQEEYVK RALANSLACQ GKYTPSGQAG AAASESLFVS
     NHAY
//
